Drugs / Divozilimab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07136389 | Mar 2025 → Jan 2026 overdue | systemic lupus erythematosus | Biocad | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05726630 | Dec 2022 → Oct 2024 overdue | systemic sclerosis | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05730699 | Dec 2022 → Jan 2025 overdue | neuromyelitis optica | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06987851 | Mar 2022 → May 2024 | multiple sclerosis | Biocad | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Divozilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05726630 ↗ |
| Known as | BCD-132 | “The goal of this clinical trial is to study the efficacy and safety of BCD-132 (divozilimab) in subjects with neuromyelitis optica spectrum disorders (NMOSD).” NCT05730699 ↗1“BCD-132 (divozilimab)” NCT06987851 ↗ |
| Action | Inhibit | “anti-CD20 therapy (divozilimab)” NCT07136389 ↗ |
| Modality | Monoclonal antibody | “Ant-CD0 human monoclonal antibody, Concentrate for solution for infusion intravenously” NCT07136389 ↗ |
| Route | Intravenous | “Concentrate for solution for infusion intravenously” NCT07136389 ↗ |